Expert Interview
Discussing the clinical landscape of NASH and the potential of Akero's Efruxifermin & Altimmunes Pemvidutide, a GLP-1/glucagon dual receptor agonist.
Ticker(s): AKRO, ALTInstitution: California Pacific Medical Center
- Hepatologist with California Pacific Medical Center’s Liver Disease Management and Transplant Program & Director of Clinical Protocols and Liver Support Services.
- Treats 50 patients per month with NASH.
- Investigates the pathophysiology and treatment of portal hypertension, hepatic encephalopathy, and liver support devices for acute and acute-on-chronic liver failure.
- Leads clinical trials of treatments for hepatic encephalopathy, hepatitis B and C, liver failure, and the management of liver transplantation.
Please describe your background and practice setting
Added By: ben_adminHow many patients with NASH do you manage?
Added By: ben_adminHow do you diagnose and measure NASH?
Added By: ben_adminWhat is your opinion of some of the ongoing GLP-1 trials: specifically Altimmune’s pemvidutide?
Added By: ben_adminHow does pemvidutide's weight loss data compare to others in this space?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
